1

Kelyniam Global

Kelyniam Global
Leadership team

Mr. Ross Bjella (Chairman & CEO)

Mr. Terrance Kurtenbach (Chief Financial Officer)

Michael Hamblett (Director of Investor Relations)

Products/ Services
Biotechnology, CAD, Manufacturing
Number of Employees
0 - 50
Headquarters
Canton Center, Connecticut, United States
Established
2005
Revenue
2M - 5M
Traded as
OTC Pink:KLYG
Social Media
Overview
Location
Summary
Kelyniam Global, Inc., a medical device manufacturing company, engages in the production of custom prosthetics utilizing computer aided design, and computer aided manufacturing of advanced medical grade polymers. The company develops, manufactures, and distributes custom cranial and craniofacial fixation screws for patients requiring the reconstruction of cranial and facial structures. It serves health systems, hospitals, sales representative, and surgeons, payors, and patients. The company was formerly known as Ketner Global Investments, Inc. and changed its name to Kelyniam Global, Inc. in December 2007. The company was incorporated in 2005 and is based in Collinsville, Connecticut.
History

Originally founded in 2002, Kelyniam was established to provide innovative medical device and healthcare technology solutions. The company has since grown to employ over 400 staff around the globe, providing medical device and healthcare technology products, services and solutions to customers around the world.

Mission
Our mission is to provide superior medical products, technologies and services to our customers, to create a safe and secure environment for our customers and employees, and to contribute to the overall well-being of the medical community.
Vision
Our vision is to create a world where people are empowered to make informed healthcare decisions using the latest medical products, technologies and services.
Key Team

Mr. James Barrow Esq. (Gen. Counsel and Director of Quality & Regulatory)

Dr. Mark V. Smith M.D. (VP of Sales & Bus. Devel. and Director)

Dr. Christopher Mirucki (Chief Medical Officer)

Recognition and Awards
Kelyniam has been awarded numerous awards, including the 2016 Forbes' Best of Year Award, the 2017 Inc. Magazine's 500|5000 Award, and the 2018 Bloomberg Top 100 Private Companies Award.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Kelyniam Global
Leadership team

Mr. Ross Bjella (Chairman & CEO)

Mr. Terrance Kurtenbach (Chief Financial Officer)

Michael Hamblett (Director of Investor Relations)

Products/ Services
Biotechnology, CAD, Manufacturing
Number of Employees
0 - 50
Headquarters
Canton Center, Connecticut, United States
Established
2005
Revenue
2M - 5M
Traded as
OTC Pink:KLYG
Social Media